The use of biological repair in infectious bone defects has been a major challenge for clinicians. With potential for bone regeneration, stem cell therapy could be an effective biological restoration measure for infection-caused bone destruction. In this study, we propose a new stem cell therapy strategy for infectious bone defect repair through systemic transplantation of human dental pulp stem cells (hDPSCs). Hypoxic preconditioning (HP) is thought to be able to enhance duration of survival and therapeutic potency of engrafted stem cells; therefore, we examined the role of HP on hDPSC therapeutic efficacy. Our results show that HP significantly enhanced hDPSC survival rate and osteogenic differentiation. hDPSCs were all CXCR4 positive under hypoxic pretreatment and their migration in response to SDF-1 was increased in vitro. hDPSC migration increase can be abolished after application of CXCR4 antagonist, AMD3100. In a mouse apical periodontitis bone destruction model, after transplantation of hypoxic preconditioned hDPSCs through intravenous injection, upregulated hDPSC recruitment and recovery of alveolar bone mass were observed in infected periapical tissue, and osteogenesis and bone mineralization were enhanced. Significantly, in periapical lesions, we found increased SDF-1 production and CXCR4/CFSE+ colabeled cells. Together, our results suggested that hypoxic preconditioned hDPSCs are capable of repairing infectious bone defects through the SDF-1/CXCR4 axis. Our investigation provides a novel infection-caused bone loss therapeutic strategy using hDPSC transplantation, and HP is an effective way of improving hDPSC survival rate, recruitment, and osteogenesis.
ThomasM.V., and PuleoD.A.Infection, inflammation, and bone regeneration: a paradoxical relationship. J Dent Res, 90, 1052, 2011.
3.
UskokovicV.Nanostructured platforms for the sustained and local delivery of antibiotics in the treatment of osteomyelitis. Crit Rev Ther Drug Carrier Syst, 32, 1, 2015.
4.
CottiE., SchirruE., AcquasE., and UsaiP.An overview on biologic medications and their possible role in apical periodontitis. J Endod, 40, 1902, 2014.
5.
ParkO.J., KimJ., YangJ., YunC.H., and HanS.H.Enterococcus faecalis inhibits osteoblast differentiation and induces chemokine expression. J Endod, 41, 1480, 2015.
6.
KikuiriT., KimI., YamazaT., AkiyamaK., ZhangQ., LiY., ChenC., ChenW., WangS., LeA.D., and ShiS.Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res, 25, 1668, 2010.
VegaA., Martin-FerreroM.A., Del CantoF., AlbercaM., GarciaV., MunarA., OrozcoL., SolerR., FuertesJ.J., HuguetM., SánchezA., and García-SanchoJ.Treatment of knee osteoarthritis with allogeneic bone marrow mesenchymal stem cells: a randomized controlled trial. Transplantation, 99, 1681, 2015.
9.
Padial-MolinaM., O'ValleF., LanisA., and MesaF.Clinical application of mesenchymal stem cells and novel supportive therapies for oral bone regeneration. Biomed Res Int, 2015, 341327, 2015.
10.
AurrekoetxeaM., Garcia-GallasteguiP., IrastorzaI., LuzuriagaJ., Uribe-EtxebarriaV., UndaF., and IbarretxeG.Dental pulp stem cells as a multifaceted tool for bioengineering and the regeneration of craniomaxillofacial tissues. Front Physiol, 6, 289, 2015.
11.
AnkrumJ., and KarpJ.M.Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med, 16, 203, 2010.
12.
HuL., YangG., HaggD., SunG., AhnJ.M., JiangN., RicuperoC.L., WuJ., RodheC.H., AschermanJ.A., ChenL., and MaoJ.J.IGF1 promotes adipogenesis by a lineage bias of endogenous adipose stem/progenitor cells. Stem Cells, 33, 2483, 2015.
13.
Naderi-MeshkinH., BahramiA.R., BidkhoriH.R., MirahmadiM., and AhmadiankiaN.Strategies to improve homing of mesenchymal stem cells for greater efficacy in stem cell therapy. Cell Biol Int, 39, 23, 2015.
14.
BuravkovaL.B., AndreevaE.R., GogvadzeV., and ZhivotovskyB.Mesenchymal stem cells and hypoxia: where are we? Mitochondrion, 19, 105, 2014.
15.
WeiN., YuS.P., GuX., TaylorT.M., SongD., LiuX.F., and WeiL.Delayed intranasal delivery of hypoxic-preconditioned bone marrow mesenchymal stem cells enhanced cell homing and therapeutic benefits after ischemic stroke in mice. Cell Transplant, 22, 977, 2013.
16.
HanK.H., KimA.K., KimM.H., KimD.H., GoH.N., and KimD.I. Enhancement of angiogenic effects by hypoxia-preconditioned human umbilical cord-derived mesenchymal stem cells in a mouse model of hindlimb ischemia. Cell Biol Int, l40, 27, 2016.
17.
KarpJ.M., and Leng TeoG.S.Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell, 4, 206, 2009.
18.
HannoushE.J., SifriZ.C., ElhassanI.O., MohrA.M., AlzateW.D., OffinM., and LivingstonD.H.Impact of enhanced mobilization of bone marrow derived cells to site of injury. J Trauma, 71, 283, 2011.
19.
ArnoB., GrassivaroF., RossiC., BergamaschiA., CastiglioniV., FurlanR., GreterM., FavaroR., ComiG., BecherB., MartinoG., and MuzioL.Neural progenitor cells orchestrate microglia migration and positioning into the developing cortex. Nat Commun, 5, 5611, 2014.
20.
CornelissenA.S., MaijenburgM.W., NolteM.A., and VoermansC.Organ-specific migration of mesenchymal stromal cells: who, when, where and why? Immunol Lett, 168, 159, 2015.
21.
YuX., LuC., LiuH., RaoS., CaiJ., LiuS., KriegelA.J., GreeneA.S., LiangM., and DingX.Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury. PLoS One, 8, 62703, 2013.
22.
BaderA.M., KloseK., BiebackK., KorinthD., SchneiderM., SeifertM., ChoiY.H., KurtzA., FalkV., and StammC.Hypoxic preconditioning increases survival and pro-angiogenic capacity of human cord blood mesenchymal stromal cells in vitro. PLoS One, 10, 0138477, 2015.
23.
ItoK., MatsuokaK., MatsuzakaK., MorinagaK., and InoueT.Hypoxic condition promotes differentiation and mineralization of dental pulp cells in vivo. Int Endod J, 48, 115, 2015.
24.
ZanT., LiH., DuZ., GuB., LiuK., and LiQ.Enhanced endothelial progenitor cell mobilization and function through direct manipulation of hypoxia inducible factor-1alpha. Cell Biochem Funct, 33, 143, 2015.
25.
KianiA.A., KazemiA., HalabianR., MohammadipourM., Jahanian-NajafabadiA., and RoudkenarM.H.HIF-1alpha confers resistance to induced stress in bone marrow-derived mesenchymal stem cells. Arch Med Res, 44, 185, 2013.
26.
MovafaghS., CrookS., and VoK.Regulation of hypoxia-inducible factor-1a by reactive oxygen species: new developments in an old debate. J Cell Biochem, 116, 696, 2015.
27.
CrisostomoP.R., WangY., MarkelT.A., WangM., LahmT., and MeldrumD.R.Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B- but not JNK-dependent mechanism. Am J Physiol Cell Physiol, 294, 675, 2008.
28.
ZhaoJ., HuL., GongN., TangQ., DuL., and ChenL.The effects of macrophage-stimulating protein on the migration, proliferation, and collagen synthesis of skin fibroblasts in vitro and in vivo. Tissue Eng Part A, 21, 982, 2015.
29.
BarrosM.A., MartinsJ.F., MariaD.A., WenceslauC.V., De SouzaD.M., KerkisA., CamaraN.O., BalieiroJ.C., and KerkisI.Immature dental pulp stem cells showed renotropic and pericyte-like properties in acute renal failure in rats. Cell Med, 7, 95, 2015.
30.
AmiriF., Jahanian-NajafabadiA., and RoudkenarM.H.In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments: in vitro augmentation of mesenchymal stem cells viability. Cell Stress Chaperones, 20, 237, 2015.
31.
SunJ., WeiZ.Z., GuX., ZhangJ.Y., ZhangY., LiJ., and WeiL.Intranasal delivery of hypoxia-preconditioned bone marrow-derived mesenchymal stem cells enhanced regenerative effects after intracerebral hemorrhagic stroke in mice. Exp Neurol, 272, 78, 2015.
32.
DingH., GaoY.S., WangY., HuC., SunY., and ZhangC.Dimethyloxaloylglycine increases the bone healing capacity of adipose-derived stem cells by promoting osteogenic differentiation and angiogenic potential. Stem Cells Dev, 23, 990, 2014.
33.
TangY.L., ZhuW., ChengM., ChenL., ZhangJ., SunT., KishoreR., PhillipsM.I., LosordoD.W., and QinG.Hypoxic preconditioning enhances the benefit of cardiac progenitor cell therapy for treatment of myocardial infarction by inducing CXCR4 expression. Circ Res, 104, 1209, 2009.
34.
HuX., WuR., JiangZ., WangL., ChenP., ZhangL., YangL., WuY., ChenH., ChenH., XuY., ZhouY., HuangX., WebsterK.A., YuH., and WangJ.Leptin signaling is required for augmented therapeutic properties of mesenchymal stem cells conferred by hypoxia preconditioning. Stem Cells, 32, 2702, 2014.
35.
LienC.Y., Chih-Yuan HoK., LeeO.K., BlunnG.W., and SuY.Restoration of bone mass and strength in glucocorticoid-treated mice by systemic transplantation of CXCR4 and cbfa-1 co-expressing mesenchymal stem cells. J Bone Miner Res, 24, 837, 2009.
36.
LiuN., PatzakA., and ZhangJ.CXCR4-overexpressing bone marrow-derived mesenchymal stem cells improve repair of acute kidney injury. Am J Physiol Renal Physiol, 305, 1064, 2013.
37.
LiuN., TianJ., ChengJ., and ZhangJ.Migration of CXCR4 gene-modified bone marrow-derived mesenchymal stem cells to the acute injured kidney. J Cell Biochem, 114, 2677, 2013.
38.
AndersenR.K., ZaherW., LarsenK.H., DitzelN., DrewsK., WruckW., AdjayeJ., AbdallahB.M., and KassemM.Association between in vivo bone formation and ex vivo migratory capacity of human bone marrow stromal cells. Stem Cell Res Ther, 6, 196, 2015.
39.
FanL., ZhangC., YuZ., ShiZ., DangX., and WangK.Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and osteogenesis in rabbit femoral head osteonecrosis. Bone, 81, 544, 2015.
40.
LiuD., WangY., JiaZ., WangL., WangJ., YangD., SongJ., WangS., and FanZ.Demethylation of IGFBP5 by histone demethylase KDM6B promotes mesenchymal stem cell-mediated periodontal tissue regeneration by enhancing osteogenic differentiation and anti-inflammation potentials. Stem Cell, 33, 2523, 2015.
41.
Roemeling-vanR.M., MensahF.K., KorevaarS.S., LeijsM.J., van OschG.J., IjzermansJ.N., BetjesM.G., BaanC.C., WeimarW., and HoogduijnM.J.Effects of hypoxia on the immunomodulatory properties of adipose tissue-derived mesenchymal stem cells. Front Immunol, 4, 203, 2013.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
